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Abstract
E6 oncoprotein derived from high-risk human papillomavirus (HPV) drives the development of cervical cancer through p53
degradation. Because cervical cancer therapies to inactivate HPV or E6 protein are not available, alternative strategies are
required. Here, we show that HPV-mediated nuclear export of human heterochromatin protein 1γ (HP1γ) reduces the
stability of p53 through UBE2L3-mediated p53 polyubiquitination during cervical cancer progression. In general, HP1 plays
a key role in heterochromatin formation and transcription in the nucleus. However, our immunostaining data showed that the
majority of HP1γ is localized in the cytoplasm in HPV-mediated cervical cancer. We found that HPV E6 protein drives
unusual nuclear export of HP1γ through the interaction between the NES sequence of HP1γ and exportin-1. The mutation of
the NES sequence in HP1γ led to nuclear retention of HP1γ and reduced cervical cancer cell growth and tumor generation.
We further discovered that HP1γ directly suppresses the expression of UBE2L3 which drives E6-mediated proteasomal
degradation of p53 in cervical cancer. Downregulation of UBE2L3 by overexpression of HP1γ suppressed UBE2L3-
dependent p53 degradation-promoting apoptosis of cervical cancer cells. Our findings propose a useful strategy to overcome
p53 degradation in cervical cancer through the blockage of nuclear export of HP1γ.
Introduction
Cervical carcinogenesis is induced by persistent high-risk
human papillomavirus (HPV) infection, which is different
from other cancers or malignant diseases [1]. Among the
fifteen carcinogenic HPV subtypes, high-risk HPV sub-
types, including HPV16 and HPV18, are associated with
~70% of the cervical cancers [2, 3]. Although the incidence
and mortality rates of patients with cervical cancer are
decreasing due to effective diagnosis and vaccines, these
methods do not cure patients who already have cervical
cancer [4]. Moreover, currently existing therapeutic options,
such as surgery, radiotherapy, and chemotherapy, are lim-
ited in patients with advanced or recurrent cervical cancers
[5, 6]. Thus, a significant number of studies are struggling
to investigate targeted therapeutics using pathogenic
mechanisms.
Oncogenic transformations by high-risk HPVs are
mediated by the viral E6 and E7 oncogenes, which are
regularly co-expressed [7]. The E7 oncoprotein dysregu-
lates the cell cycle by inactivating the retinoblastoma tumor
suppressor gene [8]. The E6 protein blocks p53-mediated
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growth arrest and apoptosis by inducing p53 degradation
[9], which is dependent on E3 ubiquitin ligase, E6AP, and
E2 ubiquitin-conjugating enzyme UBE2L3 [10–12]. Thus,
the restoration of the p53 function by blocking E6 and
E6AP-mediated degradation of p53 could be an attractive
strategy for treating cervical cancers. However, to date,
there have been no agents that can block the E6-specific
degradation of p53 in HPV-driven cervical cancers.
Heterochromatin protein 1 (HP1), a histone code reader,
specifically recognizes and binds to methylated histone H3
lysine 9 (H3K9me) [13, 14]. The mammalian HP1 family,
which comprises three isoforms (HP1α, β, and γ), plays
essential roles in various cellular processes including
the heterochromatin organization, centromere stability, tel-
omere stability, DNA repair, and cellular senescence [15–
18]. HP1 possesses three characteristic structural domains:
an amino-terminal chromodomain (CD), a flexible hinge
region, and a carboxyl-terminal chromoshadow domain
(CSD) [19]. The HP1 CD binds H3K9me [13, 20, 21],
whereas the CSD can homo- and heterodimerize and bind
proteins containing the consensus sequence PXVXL
[19, 22]. HP1 isoforms exhibit different subnuclear locali-
zation in interphase: HP1α and HP1β are centromeric
whereas HP1γ is in both euchromatic and heterochromatic
regions [15, 23], implying that HP1γ has more diverse
functions not yet discovered. Several studies have shown
that HP1 contributes to the progression of several cancers
[24–26], while there are also evidences demonstrating that
expression of HP1 isoforms is decreased in diverse tumor
tissues [17]. Adding to these controversial findings, an in-
depth understanding of the role of HP1 in cancer progres-
sion would provide an interesting target for therapy.
Here, we found that abnormal nuclear export of HP1γ,
which is mediated by exportin-1, is responsible for E6-
dependent p53 degradation. Inhibition of exportin-1 or
expression of nuclear export signal (NES)-depleted HP1γ
blocked the nuclear export of HP1γ and subsequently
restored p53 signaling reducing the tumorigenic potential of
cervical cancer cells. Genome-wide analysis identified
UBE2L3, which plays a role in p53 degradation, as a target
gene of HP1γ. Overexpression of HP1γ suppressed UBE2L3
and restored p53 stability, further inducing apoptosis of
cervical cancer cells. These observations prompted us to take
a closer look at the role of HP1γ in the cervical cancer and
provide a pathogenic rationale to treat cervical cancer.
Materials and methods
DNA constructs and antibodies
The DNA constructs used in this study were pcDNA-EGFP-
HP1β, pcDNA-EGFP-HP1γ, pcDNA-EGFP-HP1γ V32A,
pcDNA-EGFP-HP1γ I165E, pcDNA-EGFP-HP1γ W174A,
pcDNA-EGFP-HP1γ 150A, 152A, and pNCMV 16E6no*.
The mutant constructs for HP1γ were generated using site-
directed mutagenesis (pcDNA-EGFP-HP1γ V32A, pcDNA-
EGFP-HP1γ I165E, pcDNA-EGPF-HP1γ W174A, and
pcDNA-EGFP-HP1γ 150A, 152A). Anti-HP1α (Epitomics,
5346-1), anti-HP1β (Millipore, MAB3448), anti-HP1γ
(Millipore, 05-690), anti-p53 (Santa Cruz Biotechnology,
SC-126), anti-UBE2L3 (abcam, ab108936), anti-ubiquitin
(Santa Cruz Biotechnology, SC-9133), anti-Exportin-1
(Santa Cruz Biotechnology, SC-74454), anti-Bax (Santa
Cruz Biotechnology, SC-20067), anti-Noxa (Santa Cruz
Biotechnology, SC-56169), anti-Puma (Santa Cruz Bio-
technology, SC-28226), anti-Caspase 3 (abcam, ab13585-
100), anti-Flag (Sigma, F-3165), anti-GFP (Santa Cruz
Biotechnology, SC-9996), anti-α-tubulin (Santa Cruz Bio-
technology, SC-32293), anti-actin (Millipore, mab1501),
and anti-Lamin A/C (Cell Signaling Technology, #2032)
antibodies were used in this study.
Cell lines and treatment
HeLa, SiHa, CaSki, and U2OS cells were purchased from
the American Type Culture Collection (ATCC). The cells
were cultured according to the instructions from ATCC and
were maintained under a fully humidified atmosphere of
95% air and 5% CO2 at 37 °C. To inhibit exportin-1, cells
were treated with 50 nM of leptomycin B (LMB) purchased
from Sigma-Aldrich for 4 h or 100 nM of KPT-330 pur-
chased from Selleckchem for 24 h.
Doxycycline-inducible HP1γ expression
The Tet-on 3G doxycycline-inducible expression system
(Takara Bio USA, #631354) was used to promote the
expression of HP1γ inserted under the TRE3G promoter in
SiHa cells according to the manufacturer’s protocol. After
cloning HP1γ wild-type (WT) or AA mutant into the
pLVX-TRE3G-IRES vector, we gathered lentiviral super-
natants from 293T cells expressing both regulator vector
(pLVX-EF1a-Tet3G) and response vector (pLVX-TRE3G-
IRES-HP1γ WT or pLVX-TRE3G-IRES-HP1γ AA). Then,
SiHa cells were coinfected with the two viruses following
G418 selection (500 μg/ml). After incubation with or
without doxycycline (1 μg/ml) for additional 48 h, the cells
were harvested for analyses.
Knockdown of gene expression
Cells were transfected with siRNA targeting HP1α, HP1β,
HP1γ, UBE2L3, or HPV16 E6 using Lipofectamine 2000
reagent (Life Technologies) according to the manufacturer’s
protocol. The sequences of siRNAs are as follow:












HPV16 E6 sense, 5′-CCACAGUUAUGCACAGAGC-3′
HPV16 E6 antisense, 5′-GCUCUGUGCAUAACUGU
GG-3′.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue sections
were acquired from normal people and HPV-positive
precancer, endocervical adenocarcinoma, and invasive
squamous cell carcinoma patients. The 4-μm sections
were deparaffinized in xylene and rehydrated through a
graded alcohol series to distilled water. The antigen
retrieval was performed by microwave irradiation, and the
primary antibody against HP1γ (05-690, Millipore, dilu-
ted at 1:200) was then applied. The specific binding was
detected with biotinylated anti-mouse immunoglobulin,
followed by peroxidase-labeled streptavidin with 3,3′-
diaminobenzidine chromogen as substrate. Slides were
counterstained with Harris hematoxylin. All protocols and
procedures with human cervical tissues were approved
by the Yonsei University Institutional Review Board
(4-2017-0898).
Immunoblotting and immunoprecipitation
For immunoblotting, each sample was subjected to SDS-
polyacrylamide gel electrophoresis. Proteins were trans-
ferred to polyvinylidene difluoride membranes using the
semi-dry transfer (Bio-Rad). The membranes were incu-
bated overnight with the indicated primary antibodies,
followed by incubation with horseradish peroxidase-
conjugated secondary antibodies for 1 h (Abcam). The
signals were detected using chemiluminescence reagents
(Intron). For immunoprecipitation, the cells were lysed
with IP lysis buffer (HEPES 40 mM (pH 7.4) containing
120 mM NaCl, 1 mM EDTA, 50 mM NaF, 1.5 mM
Na3VO4, 10 mM β-glycerophosphate, 0.3% CHAPS,
and protease inhibitors). The lysates were centrifuged for
20 min at 13,000 rpm at 4 °C. The specific antibodies were
incubated with the supernatants overnight at 4 °C, fol-
lowed by incubation with anti-rabbit Ig-IP beads (True-
blot) for 1 h at 4 °C. The beads were spun-down for 1 min
at 2000 rpm and washed three times with IP wash buffer
(IP lysis buffer without CHAPS). The proteins were
eluted by boiling for 5 min in Laemmli buffer (Bio-Rad)
and subjected to immunoblotting.
Nuclear fractionation
For the fractionation of cytoplasmic and nuclear extracts,
cells were suspended in buffer A (10 mM HEPES con-
taining 1.5 mM MgCl2, 10 mM KCl, 1 mM EDTA, 1 mM
DTT, 0.5 μg/ml leupeptin, 1 mM PMSF, 1 μM pepstatin A,
and 0.05% NP-40), and cytoplasmic extracts were separated
by centrifugation at 4 °C at 3000 rpm for 10 min. The
remained pellet was resuspended in Buffer B (20 mM
HEPES containing 1.5 mM MgCl2, 420 mM KCl, 25%
glycerol, 0.2 mM EDTA, 1 mM DTT, 0.5 μg/ml leupeptin,
1 mM PMSF, and 1 μM pepstatin A) and incubated on ice
for 30 min. Nuclear extracts were separated by centrifuga-
tion at 4 °C at 13,000 rpm for 20 min.
Clonogenic assay
For the stable cells, SiHa cells expressing doxycycline-
inducible HP1γ WT or AA were seeded in 1 × 103 cells
per well of a six-well plate and cultured with doxycycline
(0.5 μg/ml) for 10–20 days. For transiently expressing
cells, HeLa or Siha cells were seeded in 2 × 103 cells per
well of a six-well plate. Five days after, the cells were
transfected with siRNA or DNA plasmids and the cells
were grown 3–5 days more. Cells were fixed with glu-
taraldehyde (6%) and stained with 0.5% crystal violet.
The images of stained colonies were visualized using a
digital scanner.
Tumorigenesis with the xenograft mouse model
All animal experiments were approved by the Institutional
Review Board of the Yonsei University College of
Medicine and were performed in specific pathogen-free
facilities according to the university’s guidelines for the
Care and Use of Laboratory Animals (2018–0155).
Female Balb/c nude mice (5–7 weeks old) were inoculated
subcutaneously with 3 × 106 stable SiHa cells expressing
pLVX-EF1a-Tet3G (control), pLVX-TRE3G-IRES-HP1γ
WT, or pLVX-TRE3G-IRES-HP1γ AA into each flank
under 100 µL of saline/zoletil/rompun (7:1:1) anesthesia.
Mice were randomized into groups (n= 8 per group), and
treatment was started 14 days after tumor implantation.
Doxycycline (Duchefa, Netherlands) was administered to
tumor-bearing animals orally, two times a week for
3 weeks at a dose of 50 mg/kg. From palpable tumor
formation until termination, tumor sizes were measured
every 3–4 days using calipers, and tumor volume were
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calculated with the following formula: length × width2 ×
0.5236. Mice were sacrificed in a 7.5% CO2 chamber, and
tumors were harvested for immunohistochemistry and
other analyses.
Microarray
RNA labeling and hybridization were performed by using
the Agilent One-Color Microarray-Based Gene Expres-
sion Analysis protocol (Agilent Technology, V 6.5,
2010). Briefly, 200 ng of total RNA from each sample was
linearly amplified and labeled with Cy3-dCTP. The
labeled cRNAs were purified by the RNAeasy Mini Kit
(Qiagen). The concentration and specific activity of the
labeled cRNAs (pmol Cy3/μg cRNA) were measured by
NanoDrop ND-1000 (NanoDrop). A total of 600 ng of
each labeled cRNA was fragmented by adding 5 μl 10×
blocking agent and 1 μl of 25× fragmentation buffer, and
then heated at 60 °C for 30 min. Finally, 25 μl of 2× GE
hybridization buffer was added to dilute the labeled
cRNA. Fifty microliters of hybridization solution was
dispensed into the gasket slide and assembled to the
SurePrint G3 Human Microarrays, 8 × 60 K (Agilent
Technologies, Inc). The slides were incubated for 17 h at
65 °C in an Agilent hybridization oven and then washed at
room temperature by using the Agilent One-Color
Microarray-Based Gene Expression Analysis protocol
(Agilent Technology, V 6.5, 2010). The hybridized array
was immediately scanned with an Agilent Microarray
Scanner (Agilent Technologies, Inc.). The cDNA micro-
array experiments (one-channel method) were repeated
twice and the average of two gene expression values for
each gene was used for further analysis. Statistical sig-
nificance of the expression data was determined using
LPE (Local Pooled Error) test and fold change in which
the null hypothesis was that no difference exists among 2
groups. For statistical analysis, the LPE test was used for
multiple group comparisons across all samples in the
experiment by MeV (MultiExperiment Viewer) Software.
A p value of <0.05 was considered statistically significant
and termed differentially expressed genes.
Quantitative real-time PCR (qPCR)
Total RNA was extracted using Easy-Blue reagent
(iNtRON, Korea). Then 1 μg of total RNA was reverse
transcribed into cDNA using a Reverse Transcription kit
(Promega, USA). Quantitative real-time PCR was per-
formed using KAPATM SYBR FAST qPCR (KAPABIO-
SYSTEMS) with a CFX96TM or Chromo4TM real-time
PCR detector (Bio-Rad). Relative levels of mRNA were
normalized to the values of GAPDH mRNA for each











Bax reverse, 5′-TGTCCAGCCCATGATG GTTCT-3′;
Noxa forward, 5′-AGAGCTGGAAGTCGAGTGT-3′;



















HPV16 E6 forward, 5′-GAGTCAACGGATTTGGTC
GT-3′;
HPV16 E6 reverse, 5′-CATAAATCCCGAAAAGCAA
AG-3′.
Chromatin immunoprecipitation and qPCR (ChIP-
qPCR)
Total ChIP was performed as previously described [27]. In
brief, a small portion of the cross-linked, sheared chromatin
solution was reserved as the input DNA and the remainder
was subjected to immunoprecipitation overnight at 4 °C
using antibodies. After immunoprecipitation, the recovered
chromatin fragments were subjected to qPCR using primer
pairs specific for the target gene promoter. The primer












Apoptosis of cervical cancer cells was assessed using
Annexin V-PI double staining as previously described [28].
Cells were trypsinized and stained with 0.5 mg/ml Annexin
V in binding buffer (10 mM HEPES free acid, 0.14 M NaCl,
and 2.5 mM CaCl2) for 15 min. Afterward, PI (5 mg/mL
final concentration) was added and incubated for another
15 min, then applied to a flow cytometer for data collection.
Survival analysis of cervical cancer patients
The normalized level 3 TCGA RNA sequencing data of
cervical cancer were retrieved from https://gdac.broa
dinstitute.org. A total of 61 patients with available clinical
information was analyzed for overall survival and disease-
free survival. Kaplan–Meier survival curves and log-rank
statistics were employed to evaluate time to tumor recur-
rence and overall survival. Statistical significance was when
p < 0.05.
Statistical analysis
Statistical significance was analyzed using Student’s t test
(two-tailed) and Pearson’s correlation test. Statistical dif-
ferences were determined based on a P value (*p < 0.05,
**p < 0.01, and ***p < 0.001).
Results
Abnormal nuclear export of HP1γ is induced by
high-risk HPV E6 protein
To gain insight into the putative role of HP1 on cancer
progression, we examined the subcellular localization of
three HP1 isoforms in diverse cancer samples by analyzing
publicly available immunohistochemistry data of The
Human Protein Atlas (HPA) project. HPA analysis showed
cervical cancer-specific cytoplasmic localization of HP1γ,
whereas no distinctive cancer type-specific localization of
HP1α and HP1β was observed (Supplementary Fig. S1).
Thus, we subjected cervical cancer tissue specimens to
immunohistochemical analysis for the staining of HP1γ.
Unlike that observed in normal specimens, in which HP1γ
was detected mainly in the nuclear region (Fig. 1a, upper),
HP1γ was diffused from the nucleus to the cytoplasmic
region in HPV-positive adenocarcinoma specimens (Fig. 1a,
lower). However, HP1γ in HPV-positive cervical tissues
from the precancer stage was detected only in the nucleus,
whereas cytoplasmic localization of HP1γ in cervical tissues
was observed in both adenocarcinoma and squamous cell
carcinoma (Supplementary Fig. S2). TCGA survival ana-
lysis showed that the survival of cervical cancer patients
was not significantly associated with the expression level of
CBX3 (a gene encoding HP1γ) (Supplementary Fig. S3).
These data indicate that subcellular localization of HP1γ,
rather than its expression, is closely involved in the pro-
gression of cervical cancer.
We next assessed whether the E6 oncoprotein of high-
risk HPV is responsible for the nuclear export of HP1γ.
Nuclear fractionation analysis after transfection of HPV16
E6 showed an increase in the level of cytoplasmic HP1γ and
a reduction in the level of nuclear HP1γ, both in HPV-
negative (C33A) and -positive (SiHa) cells (Fig. 1b, Sup-
plementary Fig. S4A), implying immediate nuclear export
of HP1γ by high-risk HPV infection. Furthermore, knock-
down of E6 protein using siRNA targeting HPV16 E6 in
SiHa cells (Supplementary Fig. S4B) blocked the nuclear
export of HP1γ (Fig. 1c). Several studies have reported that
E6 protein from HPV forces nuclear export of p53, which
leads to degradation of p53 by cytoplasmic proteasomes
[29–31]. We also observed that HPV E6 contributed to the
reduction of p53 protein levels in both subcellular parts,
cytoplasm and nucleus (Fig. 1b, c). While a majority of
HP1γ research has focused on its chromatic role, our data
provide insights into the cytoplasmic localization of HP1γ,
which occurs during HPV infection-mediated cancer
progression.
Exportin-1-mediated nuclear export of HP1γ is
responsible for p53 downregulation in cervical
cancer
Earlier studies have reported that exportin-1 (encoded by
XPO1) is involved in high-risk HPV-mediated elevation of
the nuclear export system [29–32]. Moreover, the analysis
of GEO profiles (GDS3233) showed a significant increase
in the expression of XPO1 in cervical cancer cell lines and
cervical cancer tissues, compared with normal cervix epi-
thelium tissues (Fig. 1d). In parallel with this finding, the
binding of HP1γ to exportin-1 was significantly increased
after the overexpression of HPV16 E6 protein (Fig. 1e).
This interaction was ablated by treatment with exportin-1
inhibitor, LMB (Fig. 2a), which subsequently induced the
nuclear accumulation of HP1γ (Fig. 2b). Nuclear export of
p53 was also inhibited by LMB treatment (Fig. 2b), which
upregulated the p53 protein level and p53-mediated tran-
scription of its target genes such as Bax, Noxa, 14-3-3σ, and
Gadd45α (Fig. 2c–e). LMB-mediated increase in p53 target
gene expression was disturbed by knockdown of p53
(Fig. 2e). Similar effects were produced by KPT-330,
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another exportin-1 inhibitor (Supplementary Fig. S4C, D).
These results suggest that exportin-1 is responsible for the
abnormal nuclear export of HP1γ as well as p53.
Given that exportin-1 usually interacts with the leucine-
rich site of its target protein, known as a NES sequence
[33], we generated an NES mutant of HP1γ containing
double alanine mutation (AA) at leucine residues 150 and
152 (Fig. 2f). The interaction between HP1γ AA mutant and
exportin-1 was markedly reduced compared with WT HP1γ
(Fig. 2g), accompanied by the nuclear accumulation of the
HP1γ AA mutant as assessed by immunofluorescence
(Fig. 2h) and cell fractionation (Fig. 2i). Intriguingly,
expression of the HP1γ AA mutant led to increases in
protein levels of p53 and apoptotic markers (Fig. 2j) as well
as the transcription of p53 target genes (Fig. 2k), compared
with those in WT HP1γ-expressing cells. Thus, the inter-
action between exportin-1 and the NES of HP1γ transports
HP1γ from the nucleus to the cytoplasm, likely involved in
the reduction of p53.
Inhibiting nuclear export of HP1γ ameliorates
tumorigenesis of cervical cancer
To investigate whether nuclear export of HP1γ is involved
in tumorigenesis of cervical cancer, we generated stable cell
lines overexpressing HP1γ using doxycycline-inducible
Fig. 1 Aberrant nuclear export
of HP1γ is induced by high-
risk HPV E6 protein. a
Immunohistochemical staining
of HP1γ protein in cervical
tissues from normal specimens
(upper) and HPV-positive
cervical adenocarcinoma
patients (lower). b Immunoblot
analysis of cytoplasmic and
nuclear extracts from C33A cells
expressing Flag-HPV16 E6.
c Immunoblot analysis of
cytoplasmic and nuclear extracts
from SiHa cells expressing
siRNA of HPV16 E6. d Box-
and-Whisker plot of relative
XPO1 expression in cervical
cancer cell lines (n= 9), normal
tissues (n= 24), and cervical




whole-cell lysates (WCL) from
C33A cells expressing Flag-
HPV16 E6.
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system (Fig. 3a). In line with the data from transiently
HP1γ-expressing cells (Fig. 2i), stable expression of HP1γ
AA slightly decreased the protein level of HP1α without
alterations in the level of HP1β (Fig. 3a). Clonogenic assay
data showed that overexpression of WT HP1γ markedly
reduced colony formation of SiHa cells, which was further
suppressed by long-term expression of HP1γ AA mutant
(Fig. 3b). Next, we evaluated the in vivo tumorigenesis of
HP1γ-expressing SiHa cells in the xenograft mouse model.
The tumorigenic capacity of SiHa cells was impeded by
overexpression of HP1γ, particularly in the HP1γ AA
mutant group (Fig. 3c). Quantification of tumor volume and
tumor weight showed a significant reduction in tumor
growth in the HP1γ AA mutant group, and a lesser extent in
WT HP1γ group (Fig. 3d, e). We then observed the
expression pattern of HP1γ by staining the histological
sections of tumor tissues from the xenograft mice. While
WT HP1γ was diffused to the cytoplasm in tumor cells
(Fig. 3f, middle), the HP1γ AA mutant was predominantly
localized at the nucleus (Fig. 3f, right). These data imply the
Fig. 2 Exportin-1-mediated nuclear export of HP1γ contributes to
p53 degradation. a Immunoblot analysis of HP1γ immunoprecipitates
(IP) and whole-cell lysates (WCL) from HeLa cells treated with or
without LMB. b Immunoblot analysis of cytoplasmic and nuclear
extracts from SiHa cells treated with or without LMB. c Immunoblot
analysis of SiHa cells treated with or without LMB. d SiHa cells were
treated with or without LMB, followed by ChIP-qPCR analysis with a
p53 antibody in the promoter regions of p53 target genes. e Immu-
noblot analysis and the mRNA levels of p53 target genes in SiHa cells
expressing siRNA of p53 in the presence or absence of LMB.
f Representation of HP1γ protein and partial CD sequence containing
nuclear export signal (NES) sequences (L150 and L152) which are
substituted with alanine in the mutant vector, HP1γ AA. g Immunoblot
analysis of HP1γ immunoprecipitates (IP) and whole-cell lysates
(WCL) from SiHa cells expressing GFP-HP1γ WT or AA mutant.
h Immunofluorescence image of GFP-HP1γ WT or AA mutant
expressed in HeLa (left) and SiHa (right) cells. i Immunoblot analysis
of cytoplasmic and nuclear extracts from SiHa cells expressing GFP-
HP1γ WT or AA mutant. j Immunoblot analysis of SiHa cells
expressing GFP-HP1γ WT or AA mutant. k The mRNA levels of p53
target genes in SiHa cells expressing GFP-HP1γ WT or AA mutant.
Data are presented as the mean ± SEM (n= 3). *P < 0.05; **P < 0.01;
***P < 0.001.
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unidentified role of HP1γ in the nucleus to prevent tumor
development.
UBE2L3 is a candidate target gene of HP1 isoforms
in cervical cancer cells
Based on the altered subcellular localization of HP1γ in
cervical cancer, we reasoned that there would be a variety of
changes in gene expression, under the control of HP1γ.
Thus, we performed a genome-wide microarray analysis of
HP1-depleted HeLa cells (Supplementary Fig. S5, Supple-
mentary Tables S1–S7). Among the candidate target genes
commonly modulated by the three HP1 isoforms (Supple-
mentary Table S1), UBE2L3 is known to be involved in
proteasomal degradation of p53 during cervical cancer
progression, interacting with E6AP to form ubiquitination
machinery (Fig. 4a) [34, 35]. Indeed, we observed sup-
pressed UBE2L3 expression and enhanced p53 signaling
upon knockdown of HPV E6 (Supplementary Fig. S6).
Depletion of UBE2L3 elevated p53 signaling, accordingly
reducing cell growth rate and colony forming ability of
cervical cancer cells (Supplementary Fig. S7). Analysis of
GEO profiles (GDS2416) in 33 different biopsies from 16
cervical cancer patients showed a negative correlation
between the expression of UBE2L3 and CBX3 (a gene
encoding HP1γ), whereas the expression of UBE2L3 and
CBX1 (a gene encoding HP1β) showed a positive correla-
tion (Fig. 4b). There was no statistically significant corre-
lation between UBE2L3 and CBX5 (a gene encoding HP1α)
levels (Fig. 4b). None of the three HP1 isoforms showed a
correlation with the expression of UBE3A, a gene coding
E6AP (Supplementary Fig. S8). The ChIP-qPCR analysis
showed that the three HP1 isoforms were differentially
recruited to the promoter of UBE2L3 as well as other can-
didate target genes (Supplementary Fig. S5D, E), indicating
that UBE2L3 is a direct target of the HP1 isoforms. In
addition, the protein level of UBE2L3 was elevated in HP1γ
knockdown cells, whereas the depletion of HP1β led to an
unexpected reduction of UBE2L3 protein (Fig. 4c). Con-
sequently, the protein level of p53 exhibited an inverse
correlation with the UBE2L3 level (Fig. 4c), which was
resulted from alterations in p53 protein stability (Fig. 4d).
None of the HP1γ or HP1β knockdown affected the TP53
mRNA level (Fig. 4e), demonstrating that the change in p53
protein level upon HP1 depletion did not originate from the
regulation of its transcription. Moreover, HP1γ depletion
Fig. 3 Inhibiting the nuclear export of HP1γ promotes p53 effects
in cervical cancer cells. a Immunoblot analysis of SiHa cells
expressing doxycycline-induced HP1 WT or AA treated with or
without doxycycline for 48 h. b Clonogenic assay of SiHa cells
expressing doxycycline-induced HP1 WT or AA treated with or
without doxycycline for 20 days. c–e In vivo tumorigenesis assay of
SiHa cells was performed. SiHa cells expressing HP1 WT or AA were
injected into the flank of nude mice. f Immunohistochemical staining
of HP1γ protein in tumor tissues derived from mice injected with SiHa
cells expressing HP1 WT or AA. Data are presented as the mean ± SD
(n= 6). *P < 0.05; **P < 0.01; ***P < 0.001.
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downregulated expression of p53 target genes, whereas
HP1β depletion produced the opposite effect (Fig. 4f). The
effects of HP1α depletion were similar to but weaker than
those of HP1γ depletion. These results indicate that HP1
isoforms differentially regulate the transcription of the
UBE2L3 gene.
HP1γ is a major regulator of UBE2L3-dependent p53
ubiquitination
As the depletion of each HP1 isoform led to a reciprocal
increase in the expression of other HP1 isoforms (Fig. 4c),
we hypothesized that the reduction in the UBE2L3 protein
level by HP1β depletion would be produced through a
compensatory response by HP1α or HP1γ. To test this, we
examined the effect of co-silencing of HP1β with another
HP1 isoform, HP1α or HP1γ, on the UBE2L3 and p53
protein levels. A reduction in UBE2L3 expression by HP1β
depletion was recovered by co-knockdown of HP1γ, but not
HP1α (Fig. 5a, b), further leading to the reduction in p53
protein level that was elevated by depletion of HP1β alone
(Fig. 5a). This effect was mediated by the alteration of
ubiquitination, but not the mRNA level of TP53 (Fig. 5c, d).
The elevation of the expressions of p53 target genes by
HP1β knockdown was also antagonized by HP1γ co-
knockdown (Fig. 5e). Critically, HP1β depletion sig-
nificantly increased the recruitment of HP1γ, but not HP1α,
to the promoter of UBE2L3 (Fig. 5f), indicating that the
upregulation of the p53 protein by HP1β depletion was due
to the suppression of UBE2L3 expression through
Fig. 4 HP1 isoforms regulate UBE2L3-dependent p53 ubiquitina-
tion in cervical cancer cells. a Model for UBE2L3-mediated p53
degradation upon high-risk HPV infection. b Pearson’s correlation
analysis in different areas of cervical cancer tumors (GDS2416) (n=
33). c Immunoblot analysis of HeLa cells expressing siRNA of HP1
isoforms. d Immunoblot analysis of p53 immunoprecipitates (IP) and
whole-cell lysates (WCL) from HeLa cells expressing siRNA of HP1
isoforms after MG-132 treatment. e The mRNA levels of TP53 in
HeLa cells expressing siRNA of HP1 isoforms. f The mRNA levels of
p53 target genes in HeLa cells expressing siRNA of HP1 isoforms.
Data are presented as the mean ± SEM (n= 3). *P < 0.05, **P < 0.01,
***P < 0.001.
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compensation by HP1γ. Indeed, inhibiting nuclear export of
HP1γ using LMB or AA mutant successfully suppressed
UBE2L3 expression (Fig. 5g, h) by recruitment of HP1γ to
the UBE2L3 promoter (Fig. 5i, j). In contrast, knockdown of
HP1α did not lead to compensatory recruitment of HP1γ to
the promoter of UBE2L3 (Supplementary Fig. S9A).
Fig. 5 HP1γ negatively regulates p53 ubiquitination by suppres-
sing UBE2L3 expression. a Immunoblot analysis of HeLa cells co-
expressing siRNA of HP1 isoforms. b The mRNA levels of UBE2L3
in HeLa cells co-expressing siRNA of HP1 isoforms. c The mRNA
levels of TP53 in HeLa cells co-expressing siRNA of HP1 isoforms.
d Immunoblot analysis of p53 immunoprecipitates (IP) and whole-cell
lysates (WCL) from HeLa cells co-expressing siRNA of HP1 isoforms
after MG-132 treatment. e The mRNA levels of p53 target genes in
HeLa cells co-expressing siRNA of HP1 isoforms. f HeLa cells were
transfected with siRNA of HP1β, followed by ChIP-qPCR analysis for
HP1α and HP1γ antibodies in the promoter region of the UBE2L3
gene. g SiHa cells were treated with or without LMB, followed by
ChIP-qPCR analysis with an HP1γ antibody in the promoter region of
the UBE2L3 gene. h The mRNA levels of UBE2L3 in SiHa cells
treated with or without LMB. i SiHa cells were transfected with GFP-
HP1γ WT or AA mutant vectors, followed by ChIP-qPCR analysis
with a GFP antibody in the promoter region of UBE2L3 gene. j The
mRNA levels of UBE2L3 in SiHa cells expressing GFP-HP1γ WT or
AA mutant. k Immunoblot analysis of HeLa cells co-expressing
siRNA of HP1γ and UBE2L3. l The mRNA levels of UBE2L3 in
HeLa cells co-expressing siRNA of HP1γ and UBE2L3. m The
mRNA levels of TP53 in HeLa cells co-expressing siRNA of HP1γ
and UBE2L3. n The mRNA levels of p53 target genes in HeLa cells
co-expressing siRNA of HP1γ and UBE2L3. Data are presented as the
mean ± SEM (n= 3). *P < 0.05, **P < 0.01, ***P < 0.001.
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To explore whether the upregulation of p53 by HP1γ is
dependent on UBE2L3 suppression, we observed the effects
of HP1γ knockdown in UBE2L3-depleted HeLa cells
(Fig. 5k, l). The reduction of p53 protein level by HP1γ
knockdown was reversed by the co-silencing of UBE2L3,
without changing mRNA level of TP53 (Fig. 5k, m), indi-
cating that the suppression of UBE2L3 expression is
required for HP1γ-mediated upregulation of p53. Con-
sistently, decreased expressions of p53 target genes upon
HP1γ knockdown were recovered by the co-knockdown of
UBE2L3 (Fig. 5n). However, the co-knockdown of HP1α
and UBE2L3 partially recovered HP1α knockdown-
mediated inhibition of p53 signaling (Supplementary Fig.
S9B, C).
To investigate whether HP1s-mediated UBE2L3 altera-
tion is dependent on HPV E6, we tested the effects of
ectopic expression of HPV16 E6 in HPV-negative cancer
cells (U2OS). Although E6 expression in U2OS cells low-
ered the level of HP1α and HP1β while upregulating HP1γ
expression (Supplementary Fig. S10A, B), enrichment of
HP1γ on UBE2L3 promoter significantly decreased (Sup-
plementary Fig. S10C). Taken together, these data demon-
strate that HP1γ mainly suppresses UBE2L3 expression to
elevate p53 signaling, which is dependent on HPV E6.
Overexpression of HP1γ promotes p53 effects by
directly suppressing UBE2L3 expression in an HPV-
positive manner
Next, we assessed whether HP1γ overexpression prevents
UBE2L3-mediated p53 degradation. Overexpression of
HP1γ in HeLa cells blocked the expression of UBE2L3
(Fig. 6a, b) and ubiquitination of p53 (Fig. 6c), resulting in
an increase in p53 protein level (Fig. 6a) but not TP53
mRNA (Fig. 6d). Moreover, p53 was significantly recruited
to the promoters of its target genes (Fig. 6e), leading to the
upregulation of their expression (Fig. 6f). In addition,
ectopic expression of HP1γ induced the expression of
apoptotic markers (Fig. 6g) and reduced the growth rate of
HeLa cells (Fig. 6h). The positive effects of HP1γ over-
expression on p53 function were further confirmed by
similar observations in other HPV-positive cervical cancer
cell lines, SiHa, and CaSki (Supplementary Fig. S11).
However, in HPV-negative cell lines (C33A HPV-negative
cervical cancer cells and U2OS osteosarcoma cells), HP1γ
overexpression had no effect on the protein levels of
UBE2L3 and p53 (Supplementary Fig. S12A) as well as the
expression of p53 target genes (Supplementary Fig. S12B).
Interestingly, HP1γ overexpression in C33A and U2OS
cells ectopically expressing HPV16 E6 produced similar
effects observed in HPV-positive cervical cancer cells
(Supplementary Fig. S12C, D). These data indicate that the
role of ectopically expressed HP1γ in p53 elevation is
specific for high-risk HPV.
Next, we checked whether overexpression of HP1β
affects the regulatory function of HP1γ in suppression of
UBE2L3. Overexpression of HP1β increased the level of
p53 and its target genes (Supplementary Fig. S13A, B), but
UBE2L3 level was not altered by HP1β overexpression
(Supplementary Fig. S13A, C). There was a slight synergy
effect by co-overexpressing HP1β and HP1γ on induction
of p53 signaling and inhibition of colony formation of
cervical cancer cells (Supplementary Fig. S13A, B, D),
while UBE2L3 suppression by HP1γ was not affected by
co-expression of HP1β (Supplementary Fig. S13C). These
data suggest that HP1β induces p53 function through an
independent mechanism of UBE2L3.
Since we observed that HP1γ recruited to the promoter
region of the UBE2L3 gene (Fig. 5F), we tested whether
chromatin binding of HP1γ is critical for the suppression of
UBE2L3 expression. We generated an HP1γ CD mutant
possessing a single-site mutation from valine 32 (V32) to
alanine (Fig. 6i), which leads to a failure in chromatin
binding [36]. As expected, HP1γ V32A was not recruited to
the promoter region of UBE2L3, whereas ectopically
expressed WT HP1γ were enriched on the promoter region
(Fig. 6j). Unlike WT HP1γ, HP1γ V32A failed to suppress
UBE2L3 expression (Fig. 6k, l), elevate the p53 protein
level (Fig. 6l), and promote transcription of p53 target genes
(Fig. 6m). These data suggest that the binding of HP1γ to
the promoter region of the UBE2L3 gene is required for
suppression of the gene and subsequent induction of
p53 signaling.
To further examine the functional involvement of the
CSD in this response, we also produced two CSD mutants
of HP1γ (Fig. 6i). The HP1γ I165E mutant disrupts
homodimerization, while the HP1γW174A mutant fails to
interact with other proteins containing the PXVXL motif
[19, 37]. Despite substantial chromatin binding of both
HP1γ CSD mutants (Fig. 6j), neither HP1γ I165E nor
HP1γ W174A suppressed UBE2L3 expression, elevated
the p53 protein level (Supplementary Fig. S14A–C), and
reduced polyubiquitination of p53 (Supplementary Fig.
S14D). Consistently, both mutants were unable to induce
apoptotic markers (Supplementary Fig. S14A), expression
of p53 target genes (Supplementary Fig. S14E), and the
growth arrest of cervical cancer cells (Supplementary Fig.
S14F). In addition, flow cytometric analysis showed an
increase in the proportion of apoptotic cells among cells
expressing WT but not mutants HP1γ (Supplementary
Fig. S14G–I). Taken together, these results indicate that
all the domains of HP1γ are required for the suppression
of UBE2L3 expression and subsequent upregulation
of p53.
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Discussion
The role of HP1γ in euchromatic gene regulation as well as
in heterochromatic formation has been suggested, because
of its unique subnuclear localization [15, 23]. Based on the
hypothesis that the three HP1 isoforms differentially reg-
ulate gene expression, we explored the effects of HP1
depletion on gene regulation throughout the human gen-
ome. Within the commonly regulated genes, we identified
an interesting target gene, UBE2L3, which contributes to
HPV-mediated proteasomal degradation of p53. Despite the
overlapping gene regulation in the microarray screening,
our data demonstrate that HP1γ is a key suppressor of
UBE2L3 expression (Fig. 4). Although HP1α and HP1β
also increased p53 level, they were not closely related to
HPV E6-mediated UBE2L3 induction or HP1γ-mediated
UBE2L3 suppression. The regulation of p53 by HP1α was
partially dependent on UBE2L3 (Supplementary Fig. S9),
while HP1β seemed to regulate p53 through a separate
mechanism from UBE2L3 (Supplementary Fig. S10). These
results suggest that the involvement of each HP1 isoform in
UBE2L3-p53 axis is different. A previous study has
Fig. 6 Overexpression of HP1γ promotes p53 signaling by directly
suppressing UBE2L3 expression. a Immunoblot analysis of HeLa
cells expressing GFP-HP1γ. b The mRNA levels of UBE2L3 in HeLa
cells expressing GFP-HP1γ. c Immunoblot analysis of p53 immuno-
precipitates (IP) and whole-cell lysates (WCL) from HeLa cells
expressing GFP-HP1γ after MG-132 treatment. d The mRNA levels of
TP53 in HeLa cells expressing GFP-HP1γ. e ChIP-qPCR analysis with
a p53 antibody in the promoter regions of p53 target genes in HeLa
cells expressing GFP-HP1γ. f The mRNA levels of p53 target genes in
HeLa cells expressing GFP-HP1γ. g Immunoblot analysis of HeLa
cells expressing GFP-HP1γ. h The growth rate of HeLa expressing
GFP-HP1γ. i Schematic representation of HP1γ protein and partial CD
sequence containing V32. j HeLa cells were transfected with GFP-
HP1γ WT or mutant (V32A, I165E, or W174A) vectors, followed by
ChIP-qPCR analysis with a GFP antibody in the promoter regions of
the UBE2L3 gene. k The mRNA levels of UBE2L3 in HeLa cells
expressing GFP-HP1γ wild-type (WT) or V32A mutant. l Immunoblot
analysis of HeLa cells expressing GFP-HP1γ WT or V32A mutant.
m The mRNA levels of p53 target genes in HeLa cells expressing
GFP-HP1γ WT or V32A mutant. Data are presented as the mean ±
SEM (n= 3). *P < 0.05; **P < 0.01; ***P < 0.001.
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revealed that the length of the hinge region connecting CD
and CSD determines the distinct binding properties of HP1
isoforms [38]. Thus, a relatively short hinge region of HP1γ
compared with that of HP1α and HP1β appears to be con-
tributing to the HP1γ’s specific action on UBE2L3 gene
regulation.
Many diseases are associated with a dysfunction of
ubiquitin signaling, with the E3 ligases being the focus.
However, recent evidence demonstrates that mutations or
impairments of the E2-conjugating enzymes can lead to
severe diseases [39]. Given their relevance to diseases, E2-
conjugating enzymes may serve as an important family of
therapeutic targets. The functional roles of several E2s in
carcinogenesis have been reported [40]. UBE2L3 is one of
the most abundant E2s in mammalian cell lines [41] and
associated with diverse cancers including hepatocellular
carcinoma [42], oral cancer [43], prostate cancer [44], and
non-small cell lung cancer [45]. Our findings show that
UBE3L3 is transcriptionally repressed by HP1γ, which is
impaired in cervical cancer cells due to the nuclear export of
HP1γ. Hence, UBE2L3 might be a potential therapeutic
target to treat cancers that are characterized by elevated
UBE2L3 expression.
During the development of cervical cancer, oncogenic
HPV E6 plays a central role by disabling the tumor-
suppressing function of p53 [11]. In this process, E6AP
interacts with UBE2L3, and this complex participates in
p53 ubiquitination [10, 12]. Hence, inhibiting the E6-
mediated degradation of p53 could be a potent strategy to
combat cervical cancer. Recent studies have identified
several strategies to inactivate E6 and E7 using RNAi,
TALEN, or CRISPR-mediated gene disruption [46–49] or
small molecules [50, 51]. However, the previous strategies
were limited to in vitro and mouse models and have not yet
been tested in human trials [46–51]. In this current study,
we present a new approach to protect p53 from E6-mediated
degradation by controlling UBE2L3 expression with HP1γ.
HP1γ negatively regulates the ubiquitin-proteasome system
(UPS)-dependent p53 degradation through the transcrip-
tional repression of UBE2L3 while increasing overall p53
protein levels and restoring p53 function (Fig. 7). Intrigu-
ingly, these effects of HP1γ were observed only in HPV-
positive cervical cancer cells but not HPV-negative cancer
cells. Considering that E6AP, rather than MDM2, is a major
E3 ubiquitin ligase in HPV-infected cervical cancer cells
[52], the effects of HP1γ we observed here was most likely
due to suppression of UBE2L3-E6AP-p53 UPS. In line with
the previous finding, HPV-positive cervical cancer cells
eventually died after overexpression of HP1γ, suggesting
that even a partial rescue of p53 is sufficient to induce
apoptosis.
Another important issue we found here is the novel role
of high-risk HPV E6 in cervical cancer progression through
the exportin-1-mediated nuclear export of HP1γ. Although
a few papers have proposed the presence of HP1γ in the
cytoplasm during maternal to embryonic transition [53] or
in myoblasts [54], disease-specific subcellular migration of
HP1γ has not been reported yet. In the case of cervical
Fig. 7 Molecular model describing p53 regulation by HP1γ-
dependent UBE2L3 suppression. a Upon high-risk HPV infection,
the E6 oncoprotein of HPV interacts with p53 and E6AP to induce
polyubiquitination and proteasomal degradation of p53. Moreover,
HPV infection induces exportin-1-mediated nuclear export of HP1γ,
thereby allowing plenty of UBE2L3 to be expressed, which results in
p53 degradation in an HPV-specific manner. b When the NES mutant
HP1γ (HP1γ AA) is overexpressed artificially in cervical cancer cells,
exportin-1 fails to transport HP1γ AA to the cytoplasm and HPV-
specific degradation of p53 is impaired due to UBE2L3 suppression by
nuclear HP1γ.
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cancer cells, HPV E6 utilizes various Karyopherin proteins
for nuclear export and import, after which it can interact
with nuclear transcription factors such as p53 [55]. The
stability and nuclear export of p53 have been reported to
rely on chromosomal regional maintenance-1/exportin-1
activity [29], which is promoted by high-risk HPV E6 [30].
Therefore, exportin-1 is very critical for cancer cell survival
and high expression of exportin-1 has been reported in
cervical cancer [56]. Interestingly, we found abnormal
cytoplasmic localization of HP1γ, which results from
increased binding with exportin-1, in HPV-infected cervical
cancer cells and tissues. Since HP1γ is observed only within
the nucleus in the precancer stage, chronic leakage of HP1γ
to the cytoplasm upon persistent infection with high-risk
HPV might be an important step in the cancer progression
of HPV-infected cells. Notably, inhibition of the nuclear
export of HP1γ rescued the p53 level and suppressed tumor
growth. These findings suggest that the enhancement of
nuclear retention of HP1γ by pharmacological intervention
would offer a potential therapeutic strategy to overcome
HPV-specific p53 degradation in cervical cancer.
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